Form 8-K - Current report:
SEC Accession No. 0001682852-25-000031
Filing Date
2025-05-01
Accepted
2025-05-01 06:31:33
Documents
14
Period of Report
2025-05-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mrna-20250501.htm   iXBRL 8-K 30223
2 EX-99.1 exhibit9912025q1pressrelea.htm EX-99.1 150435
  Complete submission text file 0001682852-25-000031.txt   320229

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrna-20250501.xsd EX-101.SCH 1788
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrna-20250501_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrna-20250501_pre.xml EX-101.PRE 12512
16 EXTRACTED XBRL INSTANCE DOCUMENT mrna-20250501_htm.xml XML 2706
Mailing Address 325 BINNEY STREET CAMBRIDGE MA 02142
Business Address 325 BINNEY STREET CAMBRIDGE MA 02142 6177146500
Moderna, Inc. (Filer) CIK: 0001682852 (see all company filings)

EIN.: 813467528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38753 | Film No.: 25899201
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)